.
ࡱ > b d f h j l n p r
! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a c d e f g h i j k l m n o p q r s t u v w x y z { | } ~ R o o t E n t r y F YM W o r k b o o k q S u m m a r y I n f o r m a t i o n ( D o c u m e n t S u m m a r y I n f o r m a t i o n 8 \ p avg B a = = x \: $8 X@ " 1 A r i a l 1 A r i a l 1 A r i a l 1 A r i a l 1 A r i a l 1 A r i a l 1 A r i a l 1 h 8 C a m b r i a 1 , 8 C a l i b r i 1 8 C a l i b r i 1 8 C a l i b r i 1 C a l i b r i 1 C a l i b r i 1 C a l i b r i 1 ? C a l i b r i 1 4 C a l i b r i 1 4 C a l i b r i 1 C a l i b r i 1
C a l i b r i 1 C a l i b r i 1 C a l i b r i 1 C a l i b r i 1 C a l i b r i 1 A r i a l / # , # # 0 " @. " ; \ - # , # # 0 " @. " 9 # , # # 0 " @. " ; [ R e d ] \ - # , # # 0 " @. " ; # , # # 0 . 0 0 " @. " ; \ - # , # # 0 . 0 0 " @. " E # , # # 0 . 0 0 " @. " ; [ R e d ] \ - # , # # 0 . 0 0 " @. " k * 3 _ - * # , # # 0 " @. " _ - ; \ - * # , # # 0 " @. " _ - ; _ - * " - " " @. " _ - ; _ - @ _ - k ) 3 _ - * # , # # 0 _ @_ . _ - ; \ - * # , # # 0 _ @_ . _ - ; _ - * " - " _ @_ . _ - ; _ - @ _ - { , ; _ - * # , # # 0 . 0 0 " @. " _ - ; \ - * # , # # 0 . 0 0 " @. " _ - ; _ - * " - " ? ? " @. " _ - ; _ - @ _ - { + ; _ - * # , # # 0 . 0 0 _ @_ . _ - ; \ - * # , # # 0 . 0 0 _ @_ . _ - ; _ - * " - " ? ? _ @_ . _ - ; _ - @ _ - ; [ $ - F C 1 9 ] d \ m m m m \ y y y y \ " 3. "
dd/mm/yy;@
dd\.mm\.yy , * P
P a > ff
` + ) ! * 8a@ @ * 4 2>4 ) K2>4 K2>4 *
KG8A;5=85*
KG8A;5=85 +& 5=56=K9 ,. 5=56=K9 [ 0 ] - 03>;>2>: 1 , 03>;>2>: 1 . 03>;>2>: 2 , 03>;>2>: 2 / 03>;>2>: 3 , 03>;>2>: 3 0 03>;>2>: 4 , 03>;>2>: 4
1 B>3 B>3 ) 2 >=B@>;L=0O OG59:0: >=B@>;L=0O OG59:0 3 0720=85& 0720=85 4 59B@0;L=K9, 59B@0;L=K9 $ 1KG=K9 5 ;>E>9" ;>E>9 6 >OA=5=85( 5 >OA=5=85 7
@8<5G0=85*
@8F5=B=K9 % 9 !2O70==0O OG59:06 !2O70==0O OG59:0 - : "5:AB ?@54C?@5645=8O> "5:AB ?@54C?@5645=8O ;*
$8=0=A>2K9 2K9 [ 0 ] = %>@>H89$ %>@>H89 X T a b l e S t y l e M e d i u m 9 P i v o t S t y l e L i g h t 1 6 8 3f f f f ̙ ̙ 3f 3 f ff 3f 3f 3 33 3 3f 33 333 \ `
@09A- ;8AB g ~R w =B5B@8:A :0?A N 2 0 5A8B8= 84 5=B820 =0B @- @ 4/ 8= 1 0 % 5 @? D; 2 0 0 @8A>2A:89 4 !1>@ $8B>35?0B>; !3 ( 65;G53>==K9 A1>@ !3 ) 2 3 D/ ? N 1 0 8D8D>@< :0?A N 3 0 N<8. !B@5?A8;A B01 4/ @0AA0A N 1 6 A ;8=>< 8 B@020<8 840 A<0=BCA G09 2 . 5 3 N 3 0 Pharmaton SA -=0;0?@8; B1 1 0 A:0- CABKH:0 01>G:0 A :>;LF>48= A8@>? 5 0 <; LN<0= =CB@85=BA ! 548:C;8F84=K9 H0<?C=L 540 1 0 0 <; 5?0=B5= :@5:><1 B01 N 4 0 @30<5B@8; B1 5 ;>=3 5 0 0 =8A 0B28O !>;L $0@0>=>2K 20==K 8EB0 0 . 5 :3. @- :8 L i b r e s s e c l i p i n v i s i b l e s u p e r N 9 ( 0 8 8 7 4 8 ) =AB8 3@0=C;K =8A A0H5 N 5 8>0AB8= :0?A 5 0 0 ;0A:- ;L 4/ ?>; @B0 $B>@>45=B 2 7 5 <; ( &5;51=K5 B@02K) 8;L=8: >;H51=0O G0H:0 A V E N T ( 8 3 3 3 ) 2 0 0 <; A @CG:0B 3 <5A 535= 54>2K9 5 0 3 5384@>= ?>@ N 2 0 5B@>38; 5=B0 35;L 4/ 45A5= 2 0 3$ 03=8O AC;LD0B @- @ 4/ 8= 2 5 % 1 0 D8B B01 3 3 0 BL5 0: F25B=>9 4 9 2 6 4 A C:@5? MDD5:B>: 1 2 @ @C4=>9 !4 5 0 3+ >43C7=8: / !0?>;8A0 =- :0 2 5 <; ( "/ 4 0 HB) - 8<. 0<0;58/ $- ; 5430B5:A+ 81>@0;= @- @0 0@48>=0B :0?A 2 5 0 <3 N 4 0 $0@<A:E8<D0@<+ 0@E0B=K5 @CG:8 :@5< 4/ @C: ?8B0B5;L=K9 8 0 =E>;8B8= A8@>? 1 2 5 D5@>= B01 1 5 0 =>& $0@8=3>A5?B B01 4/ @0AA0A A ;8=>< N 1 0 @5< 8045@3 7 5 : @5B0@4 B1 1 0 0 N 6 0 & 0DB878= :0?;8 0 . 1 % 1 5 35=( 48:;>D5=0:) @- @ 4/ 8= 7 5 <3/ 3 D0@2:0 % - 6 A 2 =5G=( 85B $>@<C;0 &8B@8@57K20B5;L C@=>A8:8 2 3 0 1 0 CB5H5AB285, @5 C:>H:> 4/ =>3 @>?>;8A 5 2 1 1 0 0 D5=- %5D0@< ACA? 1 0 0 <3/ 5 <; 1 0 0 N 5 0 + 545=FK ! OB0- -2:0;8?B N 1 0 >B :0H;O 3 5 3 "5AB- ?>;>A:8 O n e T o u c h U l t r 5 0 HB 8=B AB5@ 7 E1 0 8=4 C?O >;LDK D8;0:B8G E L A S T 0 4 0 1 1 5 - 1 7 <AB 1 5 8 - 1 7 0 / @07< 3 15652( @0<=0 :0?A N 2 0 0?>784 B01 5 0 <3+ 2 5 =4@> :0?A 6 0 0 35= $# 3. !B02@>?>;L "@0C<5;L ! B01 N 5 0 ;LD0 3 :0?A 0 . 2 5 <:3 N 6 0 0 535= CAA:89 A :54@>2 >@5E>:>;045 4 0 3 0;5=4C;0 AC?? @5:B 3>? N 1 0 Church&Dwight UK Ltd "0=K O L A ! ;L @52=8E @59 >4>1@>B5; 3>@=K9 1 . 2 20;8A B1 7 . 5 : 3>4=. ;>M M:AB@ 684: 4/ 8= 1 <; N 1 0 <<80: @- @ 1 0 % 1 <; N 1 0 4/ =0@C6 B>? B01 1 0 <3 N 3 0 0DB878= :0?;8 0 . 1 % 1 0 ; @- @ 4/ 8= 5 % 5 <; N 1 0 ! "5@2>9 D T - 0 1 !N !0;D5B:8 2;06=K5 P r e m i a l B a b y l i n e N 4 0 4/ 45B =5 0@>M 5@0 ?/ MB C? C45A0= :0?;8 2 0 ABL >?>@= AB5:;>?;0AB8:>20O' 0;LF89 3 8:><54 B01 6520B =4@>:A84 5 0GC;8 1 0 : @5B0@4 B1 1 0 0 ;5=>AB>?0 @071E20B I8:>;>B:8 2 6 - 2 8 A<) ? 5- 0:A 1 0 4/ CE>40 70 :>659 CH=>9 @0:>28=K# :A>;- %5D0@< B01 H8? 3 0 2 2 0 9- =0?5@AB:>;L @- @ 4/ 8=D 4 0 0 ;0 ?0;L<- B @- @ <0A; 1 0 0 BKA/ / <; 1 0 <;4 !0;D5B:8 2;06=K5 M E N A L I N D p r o f e s s i o n a l N 5 0 <O3:0O C?F !0;D5B:8 AB5@8;L=K5 1 0 A<E2 0 A< N 5 S t e r i l u x E S 52 ( R E F 2 3 2 0 1 7 ) "8=8407>;- :@8 B1 ?/ > 5 0 0 2- 0;KH :><040 8B@C< L i p c a r e !C?5@70I8B0 38385=8G 2 , 8 3 A 3> 45@520- !0=B8G09 4/ ?>EC45=8O 8H=O D/ ? 2 3 N 3 0 >>B@>?8; :0?A 4 0 0 <3 N 6 0 <8=078= 4@065 1 0 0 ;>G:> 'C4> C:>H:> 4/ 7030@0 D0:B>@1 0 A 28B 1 8 0 BL5 4 4 3 5 4 0I8B=>5 ?>:@KB85 1 2 ;8@3 6C=3;8 B01 62B N 6 0 A <8=5@0;0F84>20O G:0 C@=>A8:8 ( 1 1 0 0 2 ) 1 2 5 9 A>A:>9L >;LDK ==K5 E L < A S T 0 4 0 1 1 8 - 2 1 <AB 1 5 8 - 1 7 0 / @07@<C;0 =B8AB@5AA :0?A 6 9 5 ; :0?A 0 . 0 5 N 2 0 7 !0=>@8= M<C;LA8O- :0?;8 =07 0 , 1 % 1 0 <; A = AB0=>@@0;= 1 0 0 = B01 2 5 0 <3 N 1 0 0 # 0=65B0 A N D U A - C U F B O X A U AB0=40@B=0O) !0;D5B:8 2;06=K5 B i b i N 1 5 4/ 8=B8;84 D>@B5 :0?A 5 0 0 5 8EB0 A818@A:0O 1 0 @=0O :8A;>B0 ?>@ 1 0 3 0;028B ?>@ 4/ 8= 0 . 1 N 5 -:20B>@ B01 N 1 0 8H5;L ! >28=5B B1 ?/ > N 2 1 E3 5=D>;8?5= B01 ?/ > N 6 0 !;8?5:A A?@59 6 0 28=5B B1 ?/ > N 2 1 . . ==>2M9H=A >, " 8@>B>= B01 5 ??5;L35@F 5@2>B>=8: M;8:A8@ 2 5 0 <; 0ABCHLO AC? 5 0 0 = " 8B@C N 6 0 A ;NB58=>< Zentiva3 8=B M;0AB8G=K9 5 <E8 A:>9 @0AB A 70AB56:>99 5 1 2 ' "83@>2K9 3;07 " 35;L 4/ ACAB02>2 7 5 <; LEB International/IND Diagnostik D5=5: AC?? 203 1 5 0 ;>2:0 8:;>D5=0: 35;L 1 % 4 0 37 >40 ?8BL520O 0;KH:0 !?>@B 0 , 5 ; ?/ MB 1CB ( "/ 6 HB) @>65AB>65;L 35;L 1 % 8 0 3 5@A8;>= B1 N 2 1 ;0<8= B1 6 5 0 @?>@0F8O !?835;>= B01 AC1;8=32 N 5 0 7 >@?8;A @0AB8B5;L=K5 ?0AB8;:8 >B :0H;O N 2 4 A> 2: ;8=0 >2>:08= @- @ 4/ 8=D 0 . 5 % 4 0 0 <;P 59:- @L 1 . 2 5 E5 0 0 AAB>9:89 D8:A8@CNI89 =/ A =0 ?/ 43C7=8: M O L I C A R E C L A S S I C N 2 8 @07 A?@59 =070;L= 0 . 1 % 1 0 @0;= @- @0 A A0E N 8 D 59:- @L 10:B5@8F C;LB8?;0AB N 1 1 , 9 E7 , 2 A9 >A=>25 Aventis / Usifar !C<0E :@5< 4/ B5;0 7 5 4- :B82 B1 N 8 0 * %=0 @0=A:0O =0BC@ 2 5 3 4/ ;N1>3> B8?0 2>;>A 0;LE8<D0@</ $0@9=K9 M;8:A8@ >:B>@ !>;L@59 4 5 0 2K9 ?8;8=3 S t o p p r o b l e m M=7868 1 0 0 <0 N:A :=5; B01 N 1 0 0 ; @5 C:>H:> 4/ @C: ><0H:0 1 0 0 B @I8= 420=B0= :@5@18=>20O :- B0 4@065 5 0 <3 N 2 0 0 ) .3;0=M:A M:AB@0:B 684: 4/ 2=CB@ ?@8< 1 0 0 <; 59:- @L C o m f o r t N 1 2 17840= B01 4 0 5 0 0 <3 N 1 0 8=0D8= :@5< 1 % BC10 1 0 3 0;5=4C;0 ? >:A8- %5< :0?A 5 0 0 @?8;A ?0AB8;:8 N 1 2 2>- ;8==K5> Torunskie Zaklady Materialov Opatrunkowych SA/Bella Sp. z.o.o. .! $0@H8@CAA8O8 >43C7=8: ! !;8? M=4 ?;M9 D84 35;L 2 , 5 % 3 0 3C @8468B >BL5 0: G r o w S t r o n g 9 7 7 1 9 #:@5? 8 @>AB 3 7 C a n d y p i n k 1 2 2 0 =BC@= OG N 1 0 x 5 ) !C?@8<0- ?;NA 1; 3;07 3C@5F 2 MB0?0 N 1 0 #2;06=5=85 3 0 3/ 8 0 3( !8@>? G5@=8:8 =0 A>@18B5 2 5 0 2K9 ?>F5;C9 6528:0 3 . 5 3 38385=8G5A:0O 00;>:A B1 62B N 2 0 8 548- A $>@<C;0 ! @54;8?5= B01 ?/ > N 3 0 A:>@18=>20O :- B0 ?>@ 2 . 5 3% 535= CAA:89 A :54@>2 >@5E>< 4 0 3* @- :8 L i b r e s s e C l a s s i c N o r m a l C l i p 8 <5 4>@>2L52 8:@>35= $# 3. >A:20 83> >;83;N:8= @- @ 4/ 8=D 4 0 0 <;: '5@=530 ( G5@=8:0 A B@020<8) :0?;8 4/ 2=CB@ ?@8< 5 0 =0 ?>@ 1 5 0 0 =F- B 4/ ?@83 @- @0 4/ 8=D 1 0 0 <3/ 5 <; N 5 0<? 5@0?0 4 0 4>=B>F84 @- @ 4/ <5AB ?@8< 2 5 <; Ferrosan AG# 0;L70B15;820NI89 4 0 0 @0; B01 N 6 5:A8:>= AC?? 203 1 6 <3 N 1 0 ?8;0: B01 1 0 <3 N 2 5 Vramed Medana Pharma Terpol 0@0D0@= @- @ 4/ 8= 2 5 0 <3/ 2 BL 15@57>2K9 4 0 A:89 682>B8: N 1 4 0;LD07 @5B0@4 B01 ?/ > 5 = B01 ?/ > 2 . 5 <3 N 3 0 $0@<0B5:A :@5;- @0B8>D0@< 20O B8? - 2 P 0A:0 D i z a o ?;0F- :>;; 4/ >1; 3;07 >;>B0O ?;0F5=B0 2 MB N 1 0 :B82= ;8DB8=3 3 0 3/ 8 0 3 !B>?BCAA8= :0?;8 >@0;= 5 0 :;04>: X L - M:AB@01>;LH 1 HB 9 4 7 7 8 5 7>:5B 0M@>7>;L 3 0 0 4>7 1 5 ;20= B1 3 0 B8;0: ( B8;8C<) B01 1 0 <3 N 3 0 F !:8?0@ 4/ 20== @- @ A:8?840@=K9 65;BK9 2 0 0 <; A M:AB@0:B045@8; :@51@8B0=8O ;;>E>; B01 ?/ > N 5 0 ) @- :8 D i s c r e e t n o r m a l p l u s N 2 0 5654=52=K5C 01>@ 38=5: >4=>@ AB5@ N 3 ( 7- ;> D8:A N 2 , ;- :0 $>;L:<0=0, A0;D, ?5@G) @0; B01 5 0 0 7 5 <3 N 4 0 = 8EB5@- CA/ !>B5:A $0@<$8@<0 Novartis Consumer Health -=0;0?@8; B1 5 AB0=>@< M:AB@0:B 684:89 5 0 :A8= B01 1 0 0 <:3 N 1 0 0 % !C<0E :@53@520NI89 7 5 @= @- @ =0@C6= 5 0 <;( 5C;5?B8; :0?;8 4/ ?@85<0 2=CB@L 4 % 1 2 5 @B><8F5B8= 1 2 5 <3 N 1 0 I 0=406 4/ 15@5<5==KE M;0AB 4 0 6 0 1 G5@=K9 @071E20B 1545@ 1 0 6 - 1 2 0 A<) ' 535= 0@>4=K9 ! :>:>A>3;8F5@8= B01 0 . 5 <3 N 4 0 $ $5=8AB8; 5=F828@ :@5@ ( 15=F8:;0=) B01 N 5 0 & @- :8 O L A #;LB@0 W i n g s T o p D r y N 9 ( 1 3 2 7 ) =B828@0; 0;08= AC?? 203 3 0 0 =>2K 0==K D E T O X 4/ B5;0 A 3>;C1>9 3;8=>9 '09=>5 45@52> 3 5 3! !;N=O2G8: 1>;LH>3> @07<5@0( 1 5 0 0 5 ) 3 @5 C:>H:> 4/ @C: >4>@>6=8: A<O3G0NI89 1 0 0 <; "5@1878; :@5;LB0@5= @- @ 4/ 8= 7 5 <3/ 3 <; N 5 $0@B>@3/ "50B@>=
038@0 $5=N;LA :0?A N 1 0 # C@>D5= ;NA B01 ?/ > 2 0 0 <3/ 1 0 AB AC?? @5:B 5 0 <3 N 1 0
Biocodex Lab. 0=484 :@5< 1 % 2 0 3 !5; N 6 0 % >=B59=5@ 4/ AB0=40@B 1CBK;>G:8( 1 9 5 7 7 ) 3 !B2>;0B>- MDD5:B>< 0<? 2 ABL 4/ DCG59 C4=09B >B :>2 5@570 ?>G:8 5 0 3 $>@B5:A 9 >;>B>9 CA :0?;8 . 30@:>20 !4 :8H5G=K5 ?@8 :>;8B0E 5 0 AL>=- B>=8: 'C4> C:>H:> 4/ ;8F0 8 H58 '8AB>B5; ?/ 2>A? >G8I 4/ ?@>1;568 2 2 0 <;+ @5< 4/ 45B59 4 6 40 ?8BL520O !BM;@ $0@0>=>2K 0==K :>A<5B8G5A:89 ;O 3C@2 (>:>;04 ( 5 ?@54<) ) -D8@=K5 @ " B !B@5AA0" 2 <; N 5 ?8;0: B01 1 0 :50=8G5A:8E @K1 :0?A 0 , 7 5 3 ?0:5B4 5 3 N 6 0 !C<0<54 B1 1 2 5 0B 0 . 0 5 N 5 0 =0C@0= :0?;8 CH= 2 5 =878@ A M:- B>< <0;8=K C 5@2L5/ 0:87- D0@8;L=8:- B@0=AD>@A8:8 ( 1 7 0 0 2 ) 3 0 0 = A>A:>9 0;LF5 N 6 0 % C1=0O ?0AB0 ;L1045=B ?@>B82>A? 1 0 5 31 (0A8:8 A M:AB@ @>B 6 N 1 0 "5920 ?0AB0 5 0 3 07828= A?@59 =070;= 0 . 0 5 % 1 0 @ 1 0 0 3 >@D59 :0?;8 5 0 ; :0?;8 3;07= 0 . 1 % D;/ :0? 5 A;8? !;>=5=>: O2KH0NI89 0??5B8B 1 0 0 <; Belupo 8A5;L G8I0NI89 2 0 3 6C=3;8 B01 62B N 3 0 A <8=5@0;04K ACH5=K5 5 0 3 >4=8:" @- 2K V i z i t N 3 @ D>@B5 @- @ 4/ 8=B@0=07 2254 2 0 0 40: :0?;8 4/ ?@85<0 2=CB@L 1 0 <3/ <; 2 0 <; -?;0= @- @ =0@/ ?@8@4 8;;5@ 5@;8?@8; B01 2 0 <3 N 3 0 ; @53 +! # B>=878@CNI89 7 5 38 Herbapol 10= 0=8=8; B01 3 . 5 <3 N 1 2 0 "@8- 5@A8 B01 N 2 1 ' 535= CAA:89 A 87N:>;045 4 0 3" SmithKline Beecham Pharmaceuticals 0=78=>@@B5- B01 ?/ > N 3 0 $878><5@ A?@59 1 3 5 <;C @5D5 A> A;82:0=878@CNI89 5 0 3 10=:0 8=4 C?( >;;035= #;LB@0 ?0: 8 3 N 7 2:CA 0?5;LA8=09 %5@ 4/ ?@83 ACA? 4/ 2=CB@ ?@8< 2 0 0 <3/ 5 <; D; 2 0 ;8= ?>@ 4/ 8= 1 3 N 5 0 %>=4@>8B8=- :>A 28B ?0AB8;:8 $>@B5 N 3 0 8>B@548= B01 N 3 0 5?0@ ;0AA8: ?0: 1 . 0 N 5 1 (?@8F 5 4=>@07 3 - E :>9 0 . 7 E 4 0 <= <07L 4 0 BKA / 3 1 2 3 $C@0<03 :0?A 5 0 <3 N 3 0 8B@C N 3 0 >>4 Dr. Gerhard Mann Novartis Pharma GmbH 8=?>F5B8= B01 5 2538= @- @ 4/ 8= 4 0 <3/ <; 2 <; N 1 0 0<? !8=C?@5B :0?;8 1 0 0 2K9 3;07 " :0?A 3 0 0 <3 N 3 0 0;LF5 N 3 0 0:B8AC1B8; :0?A N 2 0 = D O L P H I N CAB@>9AB2> 4/ ?@>A0 ( A> A@54AB2><K2) . !0;D5B:8 2;06=K5 E F T I ' S 2 + 1 :F8O 1M=78 N 2 0 0 @>?@>B5=- 1 0 0 :0?;8 >@0;= 2 5 F8; :0?;8 =070;= 1 5 <;. !0=B8G09 4/ ?>EC45=8O 0;8=0 D/ ? 2 3 N 3 0
Avizor Int Indus Pharma >4>@>6=8:0 A>: 1 0 0 :>@48= :0?;8 2=CB@ 5 0 ;4@5:A %>B@5< N 5 0 G5@=0O A@>48=0+ 28B !$ C= @- @ 4;O 2/ < 2254 1 <; N 1 0 0@870;8O B01 ?/ > 3>? N 4 0 ! 8=:3> 8;>10 4 0 ;845:A0 CH= :0?;8 1 0 . 5 9 :50=>; ( CE>4C 70 45BL;5B5 5> ?0AB8;:8 ;8==K5 1 , 2 ;>B>9 CA 10;L70< 4/ B5;0 1 2 5 45@< ?BCAA8= :0?;8 >@0;= 2 5 <; <8=0< 78=- ! 4@065 2 5 <3 N 1 0 E 8=B M;0AB8G=K9 5 <E1 0 A9 ( N o 9 3 1 1 7 5 ) ' !C<0@ 4/ >@0;= ACA? 1 0 0 <3/ 5 <; 2 3 ;; 4/ ;8F0, H58 >;>B0O ?;0F5=B0 2 MBN 1 0 :B82= ;8DB8=3 3 6 0 3/ 6 0 3 80:0@1 B01 2 5 0 ; B01 2 5 @>20O <0B:0 2 5 3 0@;8A :0?;8 >@0;=/ =0@C6= 5 D58=- 15=7>0B =0B@8O B1 1 0 0 A;8< :@5@@5:F D83C@K 1 0 0 <; C@0=B8; 4@065 2 5 !2 0 Torrent Pharmaceuticals" !?@8=F>2:0 % - 3 A 2 =5G=- '09 >EC48= 68@>A6830NI89 :>@@>2K5 2>;>AK 8 =>3B8 :0?A 7 0 0 2A:89 28B 7- 4/ U B M C l i n i c S A 2 A>B@. 20=B0 ">=>2>5 ( ;B09A:>5) 3 0 E5;L 0 . 4 5 ;20= B1 3 0 <3 N 2 0 :A8F8;;8= B01 2 5 0 4- :B82 B1 N 4 0 " 8B0BL5 0: F25B=>9 9 2 5 8 6 A D@C:B 0@>< 8H=O 1 2 ;>= B01 5 G8AB:0 A =8BLN D;>AAB8: N 1 0 8 @8468B >BL5 8 4 7 2 6 2>9=>9 <0=8:N@ 2 E1 2 G=0O D80;:0* 84:- BL 4/ A=OB ;0:0 A G5@54>9 1 0 0 = :0?;8 3;07=K5 4 % 1 0 =NE>2 ' Novartis @B>D5= B01 2 5 40:BA A?>;. A @. >, 5D>@B0= - @- @ 4/ 8=D 6 % 5 0 0 @;>A, :>68 8 =>3B59 #A8;5==0O D>@@>==85 $>@;0:A ?>@ 4/ >@0;= @- @0 1 0 3 N 2 0 @B@870 5 @<C;0 ?0AB8;:8 N 2 4 0@A8; 4@065 3 5 D>@B5 B01 N 4 5 ( M=0;0?@8;+ 8=40?0BL5 0: G r o w S t r o n g 9 7 7 3 6 #:@5? 8 @>AB 4 4 C h o k o l a t e c o r a l 1 2 <;. Mekophar Chemical-Pharmaceutical Joint Company B@C18 @60=K5 2 0 0 3 A :0;LF85@>H55 =0AB@>5=85 D/ ? 2 3 N 2 0 D8B>G09 B>=878@CNI89 >;8>:A84>=89 AC?? 6 <3 N 1 0 $@845@< H0BL 1 5 0 @48?8= B1 5 <3 N 3 0 = @5@CG:0 0I8B=K9 4/ @C: 7 5 <; 2 ;0<8=0B= BC15, s t u n d - u p - C1=0O ?0AB0 4/ 45B59 8@ 45BAB20 5 0 <; ( 4 0 6 0 5 ) & N a t u r i n o :0@0=8; :0?A 5 0 <3 N 3 0 4 "5@@ 68@0 35;L 0=B8F5;;N;8B=K9 2 5 0 <;+ A0=B8<5B@A 8=B M;0AB8G=K9 5 <E6 A< I d e a l f l e x u n i v e r s a l A@54=5@0AB ( N o 9 3 1 3 2 1 ) 0@0<5;L 5@15=0 (0;D59 6 0 3
0;LB>:0= M:AB 684: 2 5 @D0@- $ :0?;8 3;07= 0 . 1 % 5 D5=0:) -=B5@>; :0?A 2 5 0 <3 N 1 0 $ 8=B B@C1G0BK9 N 1 =B5:A 0 . 1 0 <E1 . 5 A: 3;N:>70 N 1 8 '5@=0O A@>48=01 !0=>@8= A?@59 =07 0 . 1 % 1 0 2K9 D;0:>=) ; !0;D5B:8 2;06=K5 P r e m i a l N 2 0 4/ 8=B840 =0B M g 1 ; N 1 ?;0AB8: 1CB ( "/ 6 HB) ( 09D $>@AB0:>@ @- @ 4/ 8= 5 AB0B8;5=) @54C:B0; B1 3 5 <3 N 6 0 <@< B1 1 0 0 <3 N 2 0 C7 :0?A 0 , 1 3 N 6 ' 52><8F5B8= @- @ A?8@B =0@C6= 0 . 2 5 % 2 5 : 3;N:>70 N 1 8 5@A8: &8B@0;38= :@5< 5 0 <; 0@;8A 684:>ABL 2 5 0 @<5@ ;8F8= B01 AC1;8=32 1 0 0 ;0@>B:0 2 B @I8= 2>:@C3 3;07 - I I I # 0B@8O E;>@84 @- @ 4/ 8= 0 , 9 % 5 = B1 5 35= $# 3. 5@A0= :0?A 2 5 0 <3 N 1 0 0 Phytopharm Klenka 0DB878= :0?;8 0 . 1 % 1 0 70 5 0 0 3 :@8AB0;;8G5A:0O 5@5:8AL 2>4>@>40 @- @ 3 % 4 0 ;>= <07L 0 . 5 % 1 0 3 (0;D59 ;8AB 5 0 3 5= B1 3 0 @@B5- B01 ?/ > N 1 0 2 >2K9 ?>F5;C9 0;8=0 3 . 5 3 38385=8G5A:0O >;LB0@5= B01 @5B0@4 1 0 0 ?;5:A 4@065 N 1 0 0 1 >2K9 ?>F5;C9 8H=O 3 . 5 3 38385=8G5A:0O/ @09A- ;8AB " @>D8B 54" B5;. 8 ( 4 9 5 ) 9 3 3 8 8 5 5 4 >2K9 ?>F5;C9 ?5;LA8= 3 . 5 3 38385=8G5A:0O ;8= :0?;8 2=CB@ 5 0 >B@>?8; B1 ?/ > 8 0 0 @0 02:070 &5;L " @- @ 4/ 8= 2 . 2 5 ?8EBK A818@A:>9 1 0 <; A r o m a c o s m e t i c s D; 8=4 C? 15=5 @5B0@4 :0?A 7 5 D>;;8= B01 0 . 0 5 <3 N 1 0 6 !0;D5B:8 2;06=K5 D i v a N 2 0 4/ 8=B8@@B ><?;5:A! 0=B5;- A?@59 80; 1 3 0 3 10;; 0M@, @- :8 D i v a U l t r a D r y N 9 35;52K5 A :@K;KH:0;80= B01 ?/ > 4 0 0 ;L $0@0>=>2K 20==K 020=40 0 . 5 :3' 8:>=>@< :@5< 4/ =0@C6= ?@8;L 4/ 20==K 45BA:0O 1 9 0 3 10=:0 ?/ MB 4 0 1 0 7 =0 >A=>25 18H>D8B0 A M:AB@ G5@54K Santen Hemofarm: !C?5@> ( F5DC@>:A8@ 4/ 8= 7 5 0 : 4> 0 1 . 0 9 . 0 8 3 K.W.Innovations Co LTD% !8@>? >@H>G5: #D 1 0 0 <;( A;018B5;L=K9) 7 5;5=:8 M O L I N E A P L U S 6 0 E9 0 A< N 1 0 2?8B 1 7 0 0 <; ( 1 6 3 9 0 3 / 0 ) 5==8 B1 62B N 2 4 c ;>< 0@;8A :0?;8 >@0;=/ =0@C6= 4 0 =:>@( 8A>?@>;>;) B1 1 0 <3 N 3 0 @=8:0 / $0@4C:B Procter&Gamble 8@ 45BAB20 0B0 1 0 0 3 E8@C@3 =/ AB5@ " ABK;8 ( 7 4 3 ) >?>@= 45@52O= ?0@0) 5?0- 5@F 3@0=C;OB 4/ ?@83 @- @0 5 3 ?0: N 3 0 !5=045:A8= B1 N 1 0 87>@0; B1 2 0 0 <3 N 1 0 % "5@AC- 3>;C10O ( 6 7 6 1 ) %@0=8B5;L 10;L70< 3 0 <;* 8B0<8= ! 2 5 4=K5 B5E=>;>388 '09 >EC459 ;C1=8:0 2 3 N 3 0 :C209B ;NB58= B01 N 6 0 87>B @- @ 4/ 8= N 5 @- :8 N a t u r e l l a U l t r a m a x i N 8 =B8AB0:A :0?A 1 8 0 <3 N 5 0 0;LF8A0= :0?A 5 0 0 <3 N 2 0 ( )
!0=- 54 !>;L25=F89 :0?;8 >@0;= 2 5 <;$ "C0;5B=0O 1C;>A0A 1 4 0 3 ?0G:0 0=8=8; B01 1 . 7 5 @B5 ;8>D 4/ ?@83 @- @0 4/ 8=B5@=07 2254 5 0 40 4/ 8= 5 G:0E N 2 0 0 O L A ! ( 3 8 9 8 ) 0;B8@ $! !>;L $0@0>=>2K 20==K '5@540 0 . 5 :3 "5; B01 ?/ > N 1 0 4 !>A:0 A8;8:>= :;0AA @53C;8@C5B>: 6 + 2 HB( 1 2 0 1 8 ) "5@0D;5:A :0?A N 6 0 E 0A:0 $0@0>=>2K 0==K 4/ ;8F0 8 H58 3 6 3 ?;0F5=- :>;; :>@0;; @>7>2 83>:A8= B01 0 . 2 5 <3 N 5 0 & CF5B0< ( ?8@0F5B0 1 2 0 0 @8;>< :@5< 45BA:89 68@=K9 A 28B A D 8 E 5 0 <; =B8AB0:A :0?A 1 8 0 <3 N 2 0 + 8D84C@ ;/ D 5 4>7 N 1 0 8=A ?@>1:0 803@0 B01 ?/ > 5 0 @ 5;G53>==K9 N 3 5 0 3 803@0 B01 ?/ > 5 0 = B1 N 2 1 & >G5?@85 5 0 0 <3 N 1 4 ( 0B=K5 48A:8 N 8 0 / !0@>==85$ >=B59=5@ 4/ :>=B0:B ;8=7 A v i z o r L e n s 5=- 59 :@5@?8;A ?0AB8;:8 N 1 2 :;C1=8G=K5# 0;5@80=K M:AB@ B01 ?/ > 2 0 <3 N 5 0 D;" "5AB 4/ 4803= 15@5< K N O W N O W 5 << N 1 ! 0B5=B5:A 20; AC?? 203 7 5 @0; B1 2 0 0 @=5@535;L 35;L 3;07=>9 5 3 Merck 5@5H ;NA :0?;8 3 0 <; 535= 0@>4=K9 5BA:89 4 0 3
Ipca Lab. Ltd "5=>@8: B01 1 0 0 / 2 5 <3 N 2 8 Esparma GmbH+ @ 4/ @- @0 4;O 2/ < 2254 5 0 0 =8A- 1@> 6 0 0 = D>@B5 B1 1 0 ?8= 10:B5@8= ;8>D 4/ @- @0 4/ 2=CB@ 8 <5AB= ?@87 N 1 0 A@>: 4> 0 4 . 0 8 0==8B @- @ 4/ 8=D 1 5 % 2 0 0 <;2K9 H0B ?5@E>B8 2 0 0 ;>A 5@A5= B1 ?/ > N 4 0 %>;8A0; 35;L 1 0 3 5;>45@< :@5;>G:> 'C4> C:>H:> 4/ 7030@0 D0:B>@2 0 A 28B 1 8 0 : AB5? 70I8BK. "5AB- :0AA5B0 4/ 4803= 15@5< K N O W N O W O P T I M A N 1 ( 0DB878= :0?;8 0 . 0 5 % 1 0 :A8= B01 0 . 2 5 1 . 5 @ ?0AB8;:8 N 1 6 <OB0- Mareechi Exports/Indchemie Health Specialites 8?@ "0@8284 B01 2 0 0 <3 N 1 0 15=5 @5B0@4 :0?A 7 5 <3 N 2 0 & 535= A8@>? 1 0 0 : 4> 0 5 . 0 8 097 35;L 1 % 2 0 3 :A8:;02 ?>@ 4/ 8= 1 . 2 N 5 Schwarz Pharma+ '5@=8:0 D>@B5 B1 2 5 0 <3 N 1 0 0 28B0;0:A B01 0 , 5 3 N 2 0 5=3@8O6 (>@BK A r t e m i s 4/ ?>EC45=8O =5>?@5=>2K5 @07< L ( 7 1 - 8 1 A<) Paul Hartman 5G5@=55 4@065 + CABK@=8: N 1 2 0 Biovet Zambon Switzerland Ltd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e c t ) = B01 2 5 0 G=K9 4>:B>@ ;8=>20O AB8: !5<?@5:A :0?A 8 <3 N 1 2 2 0@8?08= ?;NA 10;L709 1 3 N 1 D; 8=4 C? Novartis/Nycomed Austria Ratiopharm India8 "5AB F r a u t e s t N 2 4;O 4803=>AB8:8 15@5<5== D o u b l e C o n t r o l 8=B =/ A 5 E1 0 N 5 0 !:8?840@=0O M<C;LA8O 15;0O 5 0 0 D5=- %5D0@ 4 0 0 BL5 0: G r o w S t r o n g 9 7 7 2 1 #:@5? 8 @>AB 0 2 L i g u i d c o p p e r 1 2 3 ACA? 4/ 8= 4 0 <3/ 1 <; 1 ;0A:- ;L 4/ ?>; @B0 0:0;NB =B8- ;0: 2 5 0 B5@0?88 P a i n G o n e ( CG:0 4;O A=OB8O 1>;8) Riclan S.A. 8:;>D5=0: @- @ 4/ 8= 7 5 <3/ 3 =E8?@5B A8@>? 5 0 B048= A8@>? 0 . 1 % 1 0 0 <; -:78D8= B1 2 5 0 <3 N 1 6 ' -?835= 8=B8< 35;L 4/ 8=B8< 38385=K 2 5 0 <; Glenmark Pharmaceuticals Ltd@ 0;L70D5 8 !830@5B0 4;O CE>40 70 ?>;- BLN @B0 4 0 0 @=5@535;L 35;L 3;07=>9 1 0 3' @8468B >BL5 4 4 5 3 7 KH0I0O >A=>20 1 2 <; C1=0O =8BL D e n t o r o l 6 5 AB0B :0?A 1 5 0 <3 N 1 :A =/ A ?>@ 4/ 8= 0 . 5 3 D; N 1 @8@>4=0O ;01>@0B>@8O #;LB@0?@>:B ;LB0@5= M; 4@065 N 6 0 &8?@>;5B B1 ?/ > 2 5 0 2>:08= @- @ 4/ 8= 0 . 5 % 5 <; N 1 0 "5BC@0< B01 1 5 0 2 0 35= $# 3. ">? :0;8=K =0 A>@18B5 2 5 0 =07>; :0?A 1 5 0 @ $8B>A540= !3 ( CA?>:>8B5;L=K9 A1>@ !3 ) 5 0 3' $;5:A8= !>;NB01 B01 48A?5@3 5 0 0 2 5 0 @0B048=- 5@B5 B01 1 0 <3 N 1 0 1 C1=0O =8BL @57845=B 5 0 @35:A848=>?84 B1 1 0 <3 N 1 0 <@@0; 5 0 <;' :0?@>=>20O :- B0 @- @ 4/ 8=D 5 % 1 0 0 ; <07L 3 0 3 A5=8:0; :0?A 1 2 0 <3 N 2 1 520;38= @- @ 4/ 8= 5 :B>@ >< ?0AB8;:8 N 2 0 ;8= -=38AB>; B1 AC1;8=32 N 5 0 - 35:A0; @- @ >@0; 8 4/ 8=30; 7 . 5 <3/ <; 5 0 @8= M<C;LA =07 0 . 1 % 1 0 2 5 <3 N 3 0 - 8=B M;0AB8G=K9 1 , 5 <E1 0 A9/ C@>D5= ACA? 4/ 45B59 1 0 0 <3/ 5 <; 1 0 0 A:8B>; !5B:0 0=B8A:8B=0O =0 45BA:CN :@>20B:C !?5F80;L=0O 70I8B0 >B =0A5:> 4/ ?@>A>3;>B:8 ?0:5B8: N 3 0 ;8>= B1 2 5 0 2538= B01 ?/ > 2 0 0 4K ACH5=K5 5 0 3 >4=8:? >40 ?8BL520O =5307 >2>B5@A:0O 3>@=0O 5 ; ?/ MB 1CB ( "/ 3 HB) 5@15=0 :0?;8 5 0 <;$ !5@= ;8>D ?>@ 4 @8B5;L 01>@0B>@8O 0B@8=/ ;L; 548- A $>@=0;L=0O <5AOG=0O A8AB5<0 :0?A 6 9 0 ? :0?A 2 0 =>2K 0==K 4/ @C: 0:0> 2 E6 3 59:- @L 2 . 0 E5 0 0 ?; ?5=0; %>@20B8OG A256 ?>;- B8 @B0 ;L1045=B >D5 8 !830@5B0 A?@59 ?@/ 2>A?0;8B5;L=K9 3 5 70 @- @ 4/ 8=D 5 % 2 0 0 =78;3>= @- @ >@0;= 1 0 0 <;+ 5F5?BK :@5<- 10;L70:0820NI89 5 0 ==K9 4 1 1 0 4 G5@=K9 @071E20B B0;88 7 7 - 9 0 AA:8B>; ;>G:> #=825@A0;L=0O 70I8B0 >B :>2 1 5 0 @ ?>40@>G=K9 V T - 0 6 V e l v e t T o u c h Nycomed/Dansk Droge 0:>@5= 5?0=B5= ;>AL>= 2 . 5 % 2 0 0 D;028= B01 ?/ > @0AB2>@/ :8H5G= N 5 0 9 "0CD>= :0?;8 3;07=K5 4 % 5 9- :0? 8=4 C?+ C;LB8- B01A .=8>@ B1 62B N 6 0 D@C:B>2K9 2:CA >?548C< :0?A 2 <3 N 1 0 " $5@;0BC< @- @ 4/ 2=CB@ ?@8< 1 5 <; N 1 0 # 5@8 2 0 0 <3 N 3 0 + ;NB020O :- B0 B01 ?/ > :HG@AB2 2 5 0 '09=>3> 45@520 1 0 =B B1 4/ @AA2 N 2 0 / ;0ABK@L L u s e r o =B8F5;;;N;8B=K9 I D P 1 2 x 1 2 A=E>B>= A8@>? 1 2 5 3 8=4 C? :B>2538= B01 ?/ > 2 0 0 N 6 0 !5B538A B01 2 @ !;018B5;L=K9 !1 5 0 3 :28>=- 535= !C?5@ :>:>A>2K9 H>:>;04 3;07C@L 3 5 3 IVAX-CRK 59:- @L M a s t e r U n i 45BA:89 5 . 7 x 1 . 9 A< !;8@ >A=>25 0A;> '09=>3> 45@520 1 . 3 <; &5@C:0; @- @ 4/ 8= 2 =0?0:A 4@065 1 0 @=8; =5G= N 4 ) :A :0?A 2 0 @48:0 :>78BC< @- @ 4/ 8= N 5 8; @- @ 4/ 8= 1 % 1 <; N 1 0 M 8A:8 2;06=K5 N 3 0 / !0:>3> >G8I5=8O 4/ 68@= 8 :>68 >;4@5:A B1 N 1 2 A 28B != >OA 3@520NI89 N 6 X X L ( @07< 5 0 - 5 2 ) 9 5 0 9 - ' 59:- @L M a s t e r U n i 2 . 0 E5 A=>20+ 535= CAA:89 >2K9 A 5A=K@5E>;>; B01 1 0 0 A?>@ < :@5A?>@ =01>@ 4/ ;5G5=8O =>3B59 ( ?;- @L) 0:A0= >2>- 0AA8B B1 ?/ > 2 0 0 @ "83@>2K9 3;07 35;L 4/ B5;0 7 5 ;0A:820B5;L 4/ ?>;>AB8 @B0 B i o t e n e 2 5 0 <; (0;D59 ?0AB8;:8 N 2 4 . 0B0 1 0 0 3 E8@C@3 =/ AB5@ " H?0= B1 1 0 0 <3 N 5 0 * 8B0<8= ! 652 B01 5 0 0 =E0;8A- %5;L B01 N 5 0 (?@8F 5 4=>@07 $8B>A >@40D5= B1 ?/ > 1 0 <3 N 5 0 <=8: :0?A 4 0 0 9 M;8:A8@ 2 5 0 <; 8=4 C? =0;L38= AC?? 2 5 0 < 0?5;LA8=0 1 0 G8AB:0 A =8BLN D;>AAB8: N 1 0 A ;>< 0@0;38= @- @ 4/ 8= 5 <; N 5 !5<0:A :0?;8 =070;= 1 % 3 "C8 70?04=>9 1 0 0 % 1 0 G:0E N 1 0 0 ( 4 0 0 5 2 ) @>2K9 25:+ >;>B>9 CA 10;L70< 4/ B5;0 1 2 5 ;4 @ 5 3 N 5 # ;>B@8;- :@8 B01 2038= 1 0 0 2A:89 28B0 70:. 0AB5@;5:' $8B>A8;0 / 5;L 8>A ; 50;0?A >@B5:A8= ?>@ 1 0 @ 2 0 0 ;>B>9 CA :0?;8 . 30@:>20 !2 65;C4>G=K5 ?@8 30AB@8B5 A ?>=86 :8A;>B 5 0 @?8;A ?0AB8;:8 N 2 4 0?5;LA8=>2K5
;B5:A B46 >ABK;L ;>:B52>9 ( 2 4 C) 4/ 27@ A @53C; ?> 2KA>B5 A5:F8O<8$ 8=B B@C1G0BK9 N 2 =B5:A 0 . 1 0 <E2 . 0 A:A8= :0?A 2 0 0 2>- 0AA8B B1 ?/ > 2 0 0 2:0 @578= - 3 2 8=4 C? IVAX/Galena# C;LB8- B01A < :84A B01 62B N 3 0 ; !0;D5B:8 2;06=K5 P r e m i a l N 2 0 4/ 8=B8<= 38385=K 28B :0?;8 4;O ACAB02>2 5 0 <; D;- :0?' 59:- @L M a s t e r U n i 5 . 0 E5 A=>20% #18E8=>= :>78BC< @- @ 4/ 8= 2 . 2 ;5B 3; :0? 3 <3/ <; 5 AL>= A0;8F8;>2K9 >3C@5G=K9 1 0 0 @>6=K5, 5::5@- 3 ( 1@8;;80=B 75;5=) 874 <54 =07= 3 20O ?0AB0 2 5 3 "5@68=0= B01 203 N 1 0 % C1=0O ?0AB0 0:0;NB $8B>D>@<C;0 5 0 <;5 59:- @L M a s t e r U n i 6 . 0 E0 . 0 8 A= A 2?8B ?>4 <=8: :0?A 4 0 0 D5=0: B01 5 0 <3 N 2 0 / C1=0O ?0AB0 0:0;NB B r i l l i a n t W h i t e M e n t a 5 0 D ?>@ 4/ 8= ?/ : 2/ < 6 4 # N 1 0 0? 1 0 0 3 8=4 C? !>A:0- CABKH:0 0=B8: 8=4 C? 5?0B@><18= ;878= @- @ 4/ 8= 1 0 B8:8 $5=075?0< B01 1 <3 N 5 0 !C;L38= B01 5 0 0 43C7=8: ! :B82 M18 :>D5@>;0 0F5B0B @- @ <0A; 1 0 % 2 0 @BA >;8:25@F5B8= B01 0 . 2 5 3 N 2 0 K >;>B>9 CA :0?;8 . 30@:>20 !1 65;C4>G=K5 ?@8 30AB@8B5 A ?>2KH :8A;>B 5 0 48? B01 1 0 <3 N 3 0 $570< :0?A N 6 0 ! "0=K O L A ! AC?5@ N 8 ( 2 2 2 3 ) + 2 HB 8=>A>; :@5= MA:C;NA 35;L 4/ =0@C6 ?@8; AC?? @5:B N 1 0 5=8B5: B1 5 2>5 AC?? @5:B 5 0 0 4 @>D8B 54 %;>A>;L @- @ 4/ 8=D 2 0 0 43C7=8: / !0;- B8 @B0 ;L1045=B 8= 3 5 @ R e N u 1 2 0 =B0:B=KE ;8=7 L=O=>5 :0?A 0 . 3 3 N 1 5 0 $ K189 68@ :0?A N 1 0 0 A 1;5?8E>9 $;>@0F84 B01 ?/ > 5 0 0 ;LB0@5= AC?? @5:B 1 0 0 <3 N 5 $0@ -@8CA A8@>? 0 . 5 <3/ <; 1 2 0 = 8B ! H8?CG B01 5 0 0 :A A?@59 3 0 43C7=8: H U G G I E S N 2 8 2 - 5 :3 LN1>@=" @5< 8045@< !3 7 5 <;( F5B8;F8AB58=- %5D0@< B01 H8? 6 0 0 @ 4/ @- @0 N 5 c 2 - x ;5B0 5?59=>5 1 0 0 @5=L ;>?CE0 M:AB- B <0A;) &K30?0= B01 4 0 0 @>2>3> 8B0=8O/ ;8=0 $0@<0F (0@;>A A M:AB@ O=B0@O 8 4- ?0=B5=>;>< 2 5 0 <;! 0;5=4C;0 =- :0 4 0 <; ( "/ 4 0 HB) 4 8=B M;0AB8G=K9 5 <E1 0 A:>9 @0AB A 70AB56:>99 5 1 2 < Mayinglong Pharmaceuticals Co/the 3-d Pharmaceutical Factory7 !0;D5B:8 2;06=K5 / !0<0O N 1 5 4/ 8=B8< 38385=K :0;5=4C;0 & $0@<0/ - <8= !C;LD0A0;078= B1 5 0 0 OA M;0AB N 3 M ( @07A;5>?5@0F8>==K9 0;0=E>5 A>: 2 0 DC@8; ACA? 4/ 2=CB ?@8< 2 0 0 <3/ 5 <; D; 9 0 <; 535= !- 28B0 5 0 3 -3;5: B01 2 0 0 <3 N 1 2 2 5;5=:8 T E R E Z A 6 0 x 9 0 , 1 5 0 0 4=>@07>2K5 "@8E>?>; B01 2 5 0 ?B8: :0?;8 3;07= 0 . 5 % 5 <;. C1:0 10==0O / !00B :>AB ( ?G5;8=K9 O4) 10;L70< 4;O B5;0 7 5 @8: B01 5 0 / 1 2 . 5 <3 N 2 8 52758 M:AB@0:B 684:89 5 0 AL>= A0;8F8;>2K9 A @><0H:9 1 0 0 <; -;8:!8 Jenapharm" 0?025@8= 3/ E; @- @ 4/ 8= 2 % 2 <; N 1 0 #=4528B 4@065 N 5 0 !C:@078B B1 N 5 0 0 70<5=8B A0E0@0 $0@4C:B@ C@>D5= 4/ 45B59 ACA? 1 0 0 <3/ 5 <; 1 0 0 <; :;C1=8G=0O A <5@=K< H?@8F55 15@30B0 =0AB>OI53> 1 0 20 B1 N 2 7 0@48><03=8; B01 7 5 @CB8= B01 N 5 0 : CABKH:0 B a b y - F r a n k 0B5:A 8H=O ;O =54>=>H5==KE ( 1 0 2 9 5 8 ) 0;480@ B1 ?/ > N 2 0 @- 2K C o n t e x N 3 R i b b e d 8; B01 5 0 A5=A>@ 6C=3;8 B01 62B N 1 0 0 $ ;0ABK@L L u s e r o =B8F5;;;N;8B=K9 N 2 8 0;L70?>;8A 2 5 0 5 54@ 0B;0AA:89 1 0 @=0O :8A;>B0 @- @ A?8@B 3 % 1 0 <; ( "/ 1 5 0 HB) 5 @54 ?>43C7=8: C@=>A8:8 A F8=:>G5?@856=>9 A> A?CA:=K< 7 5 0 :0820NI85 B@02K B01 N 1 0 + 84- A $>@<C;0 8B0 8H:8 ?0AB 6520B 2 , 4 3 N 6 0 # !C?@8@ B01 !1 6 A 2: 0?5;LA8=0
&!/ &5=B@+ 5= A59G0B:0 :0?A 4 0 0 <3 N 4 0 '09 0BMD83C@5;L 1 , 5 3 D/ ? N 2 0 . !0=B8G09 4/ ?>EC45=8O 5@A8: D/ ? 2 3 N 3 0 / $C@ M;5:B@ :@C3;K9 ( ?>4E>48B 4/ B01 8 684) <? 1 0 0 5 2 0 0 ;>B=K9 ?>1538 5 0 3 5:A0;38=- 2 5 B01 ?/ > 2 5 <3 N 1 0
$0@5:B >;30@8O :A>;
-95
:
-95
nokia 3230
motorola v3i
.